Company news

Tenaya Therapeutics, Inc. news in 2025

Tenaya Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Tenaya Therapeutics Announces Proposed Public Offering

December 11, 2025

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

December 11, 2025

Tenaya Therapeutics Announces Rapid Resolution and Lifting of Clinical Hold for MyPEAK-1™ Phase 1b/2a Clinical Trial of TN-201 Gene Therapy

December 11, 2025

Tenaya Therapeutics Announces Pricing of Public Offering

December 10, 2025

Tenaya Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 10, 2025

Tenaya Therapeutics Presents Promising Interim Clinical Data from MYPEAK™-1 Phase 1b/2a Clinical Trial of TN-201 Gene Therapy for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

November 8, 2025

Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025

November 4, 2025

Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference

October 9, 2025

Tenaya Therapeutics to Participate in Upcoming October Investor Conferences

October 2, 2025

Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

September 18, 2025

Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

September 2, 2025

Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025

August 31, 2025

Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference

August 8, 2025

Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 6, 2025

Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed

July 30, 2025

Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting

May 13, 2025

Tenaya Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025

Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025

April 24, 2025

Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting

March 31, 2025

Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models

March 24, 2025

Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session

March 19, 2025

Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 10, 2025

Tenaya Therapeutics to Participate in Upcoming March Investor Conferences

March 3, 2025

Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine

February 2, 2025

Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones

January 12, 2025

Decks in 2025